Medicare AdvantagePrior AuthLow impact
Nereus (tradipitant) capsule (New)
Humana·Family Medicine, Internal Medicine, General Practice·Medicare Advantage
Effective date
Jun 24, 2026
We identified it
Jun 24, 2026
Summary
New prior authorization policy for Nereus (tradipitant) capsule, a motion sickness medication for Medicare Advantage plans. Requires prior auth with strict criteria including age 18+, trial of meclizine/promethazine AND scopolamine patch, and use limited to intermittent travel-related motion sickness prevention.
Action Required
By June 24, 2026: Billing team must update prior authorization system to include Nereus (tradipitant) capsule for Medicare Advantage members. Verify patients meet all 5 criteria including age 18+, diagnosis of motion sickness with vomiting, failure/inability to use meclizine AND scopolamine patch, intermittent use for travel, and dosing limits. Initial approvals valid for 6 months.